High-Flow Nasal Oxygenation During Sedation for Transcatheter Aortic Valve Replacement: The HIGH-OXY-TAVR Randomised-Controlled Trial.

ABSTRACT: Background: Data on high flow nasal oxygenation (HFNO) efficacy in hypoxia prevention in transcatheter aortic valve replacement (TAVR) are conflictive. We aimed to determine the benefit of HFNO in preventing the occurrence of desaturations during TAVR. Methods: An investigator-initiated, proof of concept, single-centre, randomised, and controlled trial on 132 adult patients who were scheduled to undergo transfemoral TAVR was conducted. Patients were randomised (1:1) to HFNO (H-group) with a flow rate of 50 L min^-1 and FiO₂ 0.6 or standard of care oxygen therapy (S-group). The primary endpoint was the number of patients with a desaturation episode (SpO₂ < 93%) for >10 s during TAVR. Secondary outcomes included arterial partial pressure of oxyge

SUBMITTER: Gimenez-Mila M 

PROVIDER: S-EPMC12693371 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature